Articles tagged "Immunogenicity"

2021 American Transplant Congress
Clearance of Viral RNA and DNA and Antibody Response Following Administration of Live Attenuated Measles and Varicella Vaccines in Children with Chronic Liver Disease
S. Kemme¹, A. Weinberg², A. G. Feldman¹
¹Children's Hospital Colorado, Denver, CO, ²University of Colorado Denver, Denver, CO
*Purpose: Guidelines recommend waiting four weeks between live vaccine administration and transplantation; however, there is little data to support this waiting period and it often…
2021 American Transplant Congress
Precision Medicine in Renal Transplantation: T-cell Repertoire Sequencing to Define Donor-specific Clones for Post-transplant Monitoring
K. R. Sherwood¹, P. Wong¹, F. Fenninger¹, V. Wu¹, J. Beckrud², D. P. Cina³, L. Allan², J. Lan², P. A. Keown²
¹University of British Columbia, Vancouver, BC, Canada, ²Vancouver General Hospital, Vancouver, BC, Canada, ³Urologic Sciences, Vancouver General Hospital, Vancouver, BC, Canada
*Purpose: Measuring donor-specific clonal responses offers a precise, sensitive and specific biomarker of immune recognition and activation. Combining deep immunophenotyping (DI) and T-cell receptor (TCR)…
2021 American Transplant Congress
Hla-dq Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation and Acute Cellular Rejection After Living Donor Liver Transplantation
K. Ono, K. Ide, Y. Tanaka, M. Ohira, H. Tahara, N. Tanimine, S. Akimoto, Y. Imaoka, K. Sato, H. Yamane, N. Tsukiyama, R. Ide, T. Mochizuki, H. Ohdan
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health S, Hiroshima University, Hiroshima City, Japan
*Purpose: Epitope mismatch (MM) effect on living donor liver transplantation (LDLT) has not been studied in detail. This study aimed to investigate the role of…
2021 American Transplant Congress
Tissue Specific Antigen-presentation in VCA Transplantation
B. Kern¹, J. Mengwasser¹, A. Reutzel-Selke¹, M. I. Ashraf¹, D. Polenz¹, K. Fuehrer¹, S. Lippert¹, P. Tang¹, F. Martin¹, C. Witzel¹, I. M. Sauer¹, J. Pratschke¹, S. G. Tullius²
¹Dept. of Surgery, Charité Campus CCM|CVK, Universitaetsmedizin Berlin, Germany, Berlin, Germany, ²Division of Transplant Surgery and Transplant Surgery Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
*Purpose: Vascular Composite Tissue Allotransplantation (VCA) has become a clinical reality. High frequencies of acute rejections remain an unsolved problem. Here, we delineated components of…
2021 American Transplant Congress
HLA I Antibody-Activated Endothelium Polarized M2-Like Macrophages with Increased Efferocytic and Phagocytic Capacity
J. Nevarez-Mejia¹, X. Wei¹, N. M. Valenzuela¹, M. Rossetti¹, H. Pickering¹, G. A. Fishbein¹, A. Mulder², E. F. Reed¹
¹Pathology and Laboratory Medicine, UCLA, Los Angeles, CA, ²Immunohematology and Blood Transfusion, LUMC, Leiden, Netherlands
*Purpose: The role of intragraft macrophages (Mϕs) during antibody-mediated rejection (AMR) remains unclear. Anti-HLA Abs during AMR drives vascular inflammation as seen by monocyte recruitment…
2021 American Transplant Congress
Precision Medicine in Renal Transplantation: Structural Biology of HLA Defines Allelic Binding of Cardinal Pathogenic Viruses in Transplantation
K. R. Sherwood¹, A. Nguyen², J. Tran¹, O. Gunther³, A. Nellore², R. Thompson², J. Lan¹, L. Allan¹, P. A. Keown¹
¹Vancouver General Hospital, Vancouver, BC, Canada, ²Biomedical Engineering, Oregon Health & Science University, Portland, OR, ³Gunther Analytics, Vancouver, BC, Canada
*Purpose: The incidence, clearance and clinical expression of viremia post-Tx are heterogeneous, complicating prediction, prognosis and therapy. We postulated that variation viral presentation related to…
2021 American Transplant Congress
Limited Immunogenicity of a Single Dose of Sars-cov-2 Mrna Vaccine in Solid Organ Transplant Recipients
B. Boyarsky, M. Ou, R. Greenberg, A. Teles, W. Werbel, R. Avery, A. Tobian, A. Massie, D. Segev, J. Garonzik Wang
Johns Hopkins, Baltimore, MD
*Purpose: Given substantial challenges with vaccine allocation and evidence for short-term vaccine efficacy after a single dose of SARS-CoV-2 mRNA vaccines in clinical trials, some…
2021 American Transplant Congress
An HLA Class II Matching Strategy That Predicts De Novo Donor-specific HLA Antibody Formation Using Low Resolution HLA Types
L. Hidalgo¹, I. Martinez Juarez², L. Morales Buenrostro², S. Shojai³, P. Campbell¹
¹University of Wisconsin Madison, Madison, WI, ²Instituto Nacional de Ciencias Medicas Y Nutricion Salvador Zubrian, Mexico City, Mexico, ³Medicine, University of Alberta, Edmonton, AB, Canada
*Purpose: The development of de novo donor-specific HLA antibodies (dnDSA) is predominantly against HLA-Class II antigens and is a function of the degree of HLA-DQ…
2020 American Transplant Congress
Molecular Features of HLA Mismatches as Predictors of De Novo DSA Development: A Single Center Experience
V. Jucaud¹, L. Rebellato², K. Briley², C. Haisch², S. Kendrick³, H. Jones³, K. Mclawhorn³, D. Leeser², M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²East Carolina University, Greenville, NC, ³Eastern Nephrology Associates, Greenville, NC
*Purpose: Several molecular features (MoFs) of HLA mismatches (MMs) are currently used to predict the development of de novo donor-specific anti-HLA antibodies (dnDSA). The purpose…
2020 American Transplant Congress
HLA Mismatch Immunogenicity: Are We Predicating Mismatches That Induce De Novo DSA Development or That Do Not?
V. Jucaud¹, L. Rebellato², K. Briley², C. Haisch², S. Kendrick³, H. Jones³, K. Mclawhorn³, D. Leeser², M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²East Carolina University, Greenville, NC, ³Eastern Nephrology Associates, Greenville, NC
*Purpose: Although the development of de novo donor-specific anti-HLA antibodies (dnDSA) remains a major risk factor for poor long-term kidney allograft outcomes, the prediction of…

1
2
3
…
10
Next Page »